P04585 (POL_HV1H2) Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Gag-Pol polyprotein UniProtKBInterProInteractive Modelling
1435 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
264 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| HIV-1 Reverse Transcriptase in complex with inhibitor GSK560 |
Heteromer | 3×MG; 1×SRT; 1×WHU; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase Y188L mutant in complex with inhibitor GSK560 |
Heteromer | 3×MG; 1×TAR; 1×WHU; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with inhibitor GSK952 |
Heteromer | 1×MG; 1×TAR; 1×CXD; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase in complex with DNA that has incorporated EFdA-MP at the P-(post-transl… |
Heteromer | 1×MG; 2×6FM; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase in complex with DNA that has incorporated a mismatched EFdA-MP at the N… |
Heteromer | 1×MG; 2×6FM; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase in complex with DNA that has incorporated EFdA-MP at the P-(post-transl… |
Heteromer | 1×MG; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with inhibitor GSK500 |
Heteromer | 1×TAR; 1×EUR; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with inhibitor |
Heteromer | 1×LP8; 2×MN; 1×NVP; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Reverse Transcriptase (RT) in Complex with a triazole derived NNRTI |
Heteromer | 1×TT1; 1×GOL; 5×SO4; 5×CL; 1×MG; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and d4T |
Heteromer | 1×D4M; 4×SO4; 3×MG; 1×D4T; 1×GOL; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and L-ddCTP |
Heteromer | 2×MG; 1×NQ4; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 wild-type reverse transcriptase-DNA complex with (+)-FTC-TP |
Heteromer | 2×SO4; 1×MG; 1×N8G; | ||||
| Assess | ||||||
| HIV reverse transcriptase in complex with inhibitor R8e |
Heteromer | 1×R8E; | ||||
| Assess | ||||||
| crystal structure of HIV reverse transcriptase in complex with inhibitor 7 |
Heteromer | 1×RT7; | ||||
| Assess | ||||||
| HIV-1 RT with AMINOPYRIMIDINE NNRTI |
Heteromer | 1×DJZ; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and d4T |
Heteromer | 1×D4T; 2×MG; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with inhibitor |
Heteromer | 2×MN; 1×LP7; 1×NVP; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with inhibitor |
Heteromer | 1×LP9; 2×MN; | ||||
| Assess | ||||||
| HIV reverse transcriptase Y181C mutant in complex with inhibitor R8e |
Heteromer | 1×R8E; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase with aminopyrimidine inhibitor 2 |
Heteromer | 2×MN; 1×JGZ; | ||||
| Assess | ||||||
| Structure of HIV-1 reverse transcriptase in complex with an RNase H inhibitor and nevirapine |
Heteromer | 1×NVP; 2×MN; 2×SO4; 2×CL; 1×P4Y; | ||||
| Assess | ||||||
| Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor pote… |
Heteromer | 2×2KW; | ||||
| Assess | ||||||
| HIV-1 wild-type reverse transcriptase-DNA complex with (-)-3TC-TP |
Heteromer | 1×1RZ; 2×SO4; 1×MG; | ||||
| Assess | ||||||
| HIV-1 M184V reverse transcriptase-DNA complex with (-)-FTC-TP |
Heteromer | 1×1RY; 2×SO4; 1×MG; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and (-)-FTC |
Heteromer | 2×MG; 1×43X; 2×SO4; 1×DG; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase in complex with DNA |
Heteromer | 3×SO4; 1×MG; | ||||
| Assess | ||||||
| Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface |
Heteromer | 1×NVP; | ||||
| Assess | ||||||
| +3 extended HIV-1 reverse transcriptase initiation complex core (displaced state) |
Heteromer | |||||
| Assess | ||||||
| HIV-1 RT with non-nucleoside inhibitor annulated Pyrazole 1 |
Heteromer | 1×PZL; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase (K103N mutant) in complex with inhibitor M06 |
Heteromer | 1×M06; | ||||
| Assess | ||||||
| HIV-1 RT with pyridazinone non-nucleoside inhibitor |
Heteromer | 2×PDZ; | ||||
| Assess | ||||||
| HIV-1 RT with NNRTI TMC-125 |
Heteromer | 1×65B; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase-DNA complex with nuceotide inhibitor GS-9148-diphosphate bound in nucle… |
Heteromer | 3×SO4; 2×MG; 1×914; | ||||
| Assess | ||||||
| HIV-1 wild-type reverse transcriptase-DNA complex with (-)-FTC-TP |
Heteromer | 4×SO4; 1×MG; 1×1RY; | ||||
| Assess | ||||||
| HIV-1 wild-type reverse transcriptase-DNA complex with dCTP |
Heteromer | 1×DCP; 3×SO4; 1×MG; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase-DNA complex with GS-9148 terminated primer |
Heteromer | 1×MG; 2×SO4; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase-DNA complex with dATP bound in the nucleotide binding site |
Heteromer | 3×SO4; 2×MG; 1×DTP; | ||||
| Assess | ||||||
| +3 extended HIV-1 reverse transcriptase initiation complex core (pre-translocation state) |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of HIV RT in complex with BILR0355BS |
Heteromer | 1×GLC; 1×MLA; 1×1WT; | ||||
| Assess | ||||||
| Structure of HIV-1 RT complexed with RNA/DNA hybrid in an RNA hydrolysis-off mode |
Heteromer | 1×EFZ; 2×CA; 4×GOL; 1×PEG; | ||||
| Assess | ||||||
| Structure of HIV-1 RT complexed with RNA/DNA hybrid in the RNA hydrolysis mode |
Heteromer | 1×EFZ; 2×CA; 6×GOL; 1×TAM; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and dCTP |
Heteromer | 2×SO4; 1×DCP; 2×MG; | ||||
| Assess | ||||||
| HIV-1 M184V reverse transcriptase-DNA complex with dCTP |
Heteromer | 1×DCP; 2×SO4; 2×MG; | ||||
| Assess | ||||||
| HIV-1 M184V reverse transcriptase-DNA complex |
Heteromer | 1×MG; 3×SO4; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and (+)FTC-TP |
Heteromer | 3×SO4; 2×MG; 1×N8G; 1×GOL; | ||||
| Assess | ||||||
| Structure of HIV-1 RT complexed with an RNA/DNA hybrid sequence non-preferred for RNA hydrolysis |
Heteromer | 1×EFZ; 1×CA; 4×GOL; 1×TAM; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with dsDNA and D-ddCTP |
Heteromer | 1×DCT; 1×MG; 2×SO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE |
Heteromer | 1×NVP; | ||||
| Assess | ||||||
| Structure of HIV-1 RT complexed with an RNA/DNA hybrid containing the polypurine-tract sequence |
Heteromer | 1×EFZ; 2×CA; 2×GOL; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ) |
Heteromer | 1×EFZ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TNK-651 |
Heteromer | 1×TNK; | ||||
| Assess | ||||||
| Structure of HIV-1 Reverse Transcriptase (RT) in complex with DNA AND (-)FTC-TP |
Heteromer | 1×1RY; 2×MG; 3×SO4; | ||||
| Assess | ||||||
| HIV-1 RT with pyridone non-nucleoside inhibitor |
Heteromer | 1×3OB; | ||||
| Assess | ||||||
| Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface |
Heteromer | 1×EFZ; 2×CA; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in Complex with TMC125 |
Heteromer | 1×65B; 5×SO4; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in Complex with TMC278 |
Heteromer | 1×T27; 5×SO4; | ||||
| Assess | ||||||
| HIV-1 K103N Reverse Transcriptase in Complex with TMC125 |
Heteromer | 1×65B; 6×SO4; 1×CL; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with 6-membered bicyclic core NNRTI |
Heteromer | 1×ZJ2; 1×TLA; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with 5-membered bicyclic core NNRTI |
Heteromer | 1×YO9; 1×TLA; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with 7-membered bicyclic core NNRTI |
Heteromer | 1×XRL; 1×TLA; | ||||
| Assess | ||||||
| HIV-1 K103N Reverse Transcriptase in Complex with TMC278 |
Heteromer | 1×T27; 5×SO4; | ||||
| Assess | ||||||
| Structures of HIV-1 RT and RNA-DNA Complex Reveal a Unique RT Conformation and Substrate Interface |
Heteromer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE |
Heteromer | |||||
| Assess | ||||||
| HIV reverse transcriptase K103N mutant in complex with inhibitor R8D |
Heteromer | 1×R8D; | ||||
| Assess | ||||||
| Crystal Structure of K101E Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X. |
Heteromer | 1×HBQ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y181C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-2 |
Heteromer | 1×FTC; | ||||
| Assess | ||||||
| crystal structure of HIV reverse transcriptase in complex with inhibitor 3 |
Heteromer | 1×RT3; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with a 2,6-difluorophenyl DAPY analog |
Heteromer P0C6F2; | 1×IB1; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GCA-186 |
Heteromer | 1×GCA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-2… |
Heteromer | 1×EFZ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-2 (PETT130A94) |
Heteromer | 1×FTC; | ||||
| Assess | ||||||
| X-ray Snapshot of HIV-1 Protease in Action: Observation of Tetrahedral Intermediate and Its SIHB wi… |
Heteromer | |||||
| Assess | ||||||
| Crystal Structure of Y188C Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X. |
Heteromer | 2×PO4; 1×HBQ; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Reverse Transcriptase in Complex with GW420867X. |
Heteromer | 3×PO4; 1×MG; 1×HBQ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIR… |
Heteromer | 1×NVP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 739W94 |
Heteromer | 1×SBN; | ||||
| Assess | ||||||
| Crystal structure of hiv-1 reverse transcriptase in complex with GW564511. |
Heteromer | 2×PO4; 1×GWE; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TNK-6123 |
Heteromer | 1×612; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BM+50.0934 |
Heteromer | 1×BM5; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE |
Heteromer | 1×NVP; | ||||
| Assess | ||||||
| Crystal structure of hiv-1 reverse transcriptase in complex with GF128590. |
Heteromer | 1×GFA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF Y188C MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH UC-781 |
Heteromer | 1×UC1; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW490745 |
Heteromer | 1×GWB; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ) |
Heteromer | 1×EFZ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BM+21.1326 |
Heteromer | 1×BM1; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH PETT-1 (PETT131A94) |
Heteromer | 1×FPT; | ||||
| Assess | ||||||
| Crystal Structure of E138K Mutant HIV-1 Reverse Transcriptase in Complex with Nevirapine |
Heteromer P03367; | 3×PO4; 1×MG; 1×NVP; | ||||
| Assess | ||||||
| Crystal Structure of K101E Mutant HIV-1 Reverse Transcriptase in Complex with Nevirapine |
Heteromer P03367; | 3×PO4; 1×MG; 1×NVP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW426318 |
Heteromer | 3×PO4; 1×MG; 1×H12; | ||||
| Assess | ||||||
| Crystal Structure of L100I Mutant HIV-1 Reverse Transcriptase in Complex with GW420867X. |
Heteromer | 1×PO4; 1×HBQ; | ||||
| Assess | ||||||
| Crystal structure of hiv-1 reverse transcriptase in complex with gw450557 |
Heteromer | 3×PO4; 1×H20; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW429576 |
Heteromer | 3×PO4; 1×H16; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH GW451211 |
Heteromer | 3×PO4; 1×H18; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase crosslinked to template-primer with tenofovir-diphosphate bound as the … |
Heteromer P03366; | 2×MG; 1×TNV; 5×GOL; | ||||
| Assess | ||||||
| STRUCTURE OF A CATALYTIC COMPLEX OF HIV-1 REVERSE TRANSCRIPTASE: IMPLICATIONS FOR NUCLEOSIDE ANALOG… |
Heteromer P03366; | 4×MG; 1×TTP; | ||||
| Assess | ||||||
| Crystal structure of K103N mutant HIV-1 reverse transcriptase in complex with GW678248. |
Heteromer A7YKL0; | 1×PO4; 1×GWJ; | ||||
| Assess | ||||||
| +1 extended HIV-1 reverse transcriptase initiation complex core (pre-translocation state) |
Heteromer P03366; | |||||
| Assess | ||||||
| +3 extended HIV-1 reverse transcriptase initiation complex core (intermediate state) |
Heteromer P03366; | |||||
| Assess | ||||||
| Crystal structure of HIV-1 integrase catalytic core in complex with Fab |
Heteromer | |||||
| Assess | ||||||
| STRUCTURAL CHARACTERIZATION OF A 39 RESIDUE SYNTHETIC PEPTIDE CONTAINING THE TWO ZINC BINDING DOMAI… |
Heteromer P24740; | 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of DR11 presenting the gag293 epitope |
Heteromer P01903; P01911; | 1×NAG; 2×NAG; 5×SO4; 3×NA; 2×ACT; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 14mer peptide |
Heteromer O78189; P61769; | 2×GOL; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 13mer peptide |
Heteromer O78189; P61769; | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of DR11 presenting the RQ13 peptide |
Heteromer P01903; P01911; | 1×NAG; 2×NAG; 8×SO4; 3×NA; | ||||
| Assess | ||||||
| Crystal structure of F24 TCR -DR11-RQ13 peptide complex |
Heteromer A0A0B4J272; A0A5B9; P01903; P01911; | 2×NAG; 3×MG; | ||||
| Assess | ||||||
| Crystal structure of DR15 presenting the RQ13 peptide |
Heteromer P01903; P01911; | 2×NAG; 1×PGE; 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of F5 TCR -DR11-RQ13 peptide complex |
Heteromer A0A0B4J272; A0A0G2JMB4; P01903; P01911; | 2×NAG; 4×SO4; 2×CL; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of DR1 presenting the RQ13 peptide |
Heteromer P01903; P01911; | 2×PEG; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of F24 TCR -DR15-RQ13 peptide complex |
Heteromer A0A0B4J272; A0A5B9; P01903; P01911; | 1×NAG; 2×MG; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of F24 TCR -DR1-RQ13 peptide complex |
Heteromer A0A0B4J272; A0A5B9; P01903; P01911; | 1×NAG; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 11mer peptide |
Heteromer O78189; P61769; | 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of HLA-B*2703 in complex with KK10, an HIV peptide |
Heteromer P01889; P61769; | 1×MG; | ||||
| Assess | ||||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P61769; | 7×EDO; | ||||
| Assess | ||||||
| The structure of HLA-A*3001/RT313 |
Heteromer P04439; P61769; | |||||
| Assess | ||||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P61769; | 11×EDO; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of HLA-B*5301 complex with an HIV-1 Gag-derived epitope QW9 |
Heteromer P61769; S6BVK3; | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of HLA-B35 in complex with a pepetide antigen |
Heteromer P01889; P61769; | |||||
| Assess | ||||||
| TCR55 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P01889; P61769; Q6IRV4; | 3×EDO; 5×SO4; | ||||
| Assess | ||||||
| HLA class I micropolymorphisms determine peptide-HLA landscape and dictate differential HIV-1 escap… |
Heteromer P01889; P61769; | 6×EDO; 1×GOL; 1×SO4; | ||||
| Assess | ||||||
| The structure of HLA-A*3003/RT313 |
Heteromer A0A173ADK6; P61769; | |||||
| Assess | ||||||
| Structure of chimeric HLA-A*11:01-A*02:01 bound to HIV-1 RT peptide |
Heteromer P61769; | |||||
| Assess | ||||||
| Crystal structure of HLA-B*5701 complex with an HIV-1 Gag-derived epitope QW9 |
Heteromer P61769; U6BR87; | 1×MES; 1×IPA; | ||||
| Assess | ||||||
| Crystal Structure of the cross-restricted T18A TCR and HLAB8101 bound to HIV-1 Gag TL9 peptide |
Heteromer I3ZN85; P61769; | |||||
| Assess | ||||||
| Crystal structure of HLA-A2 in complex with LILRB1 |
Heteromer P04439; P61769; Q8NHL6; | |||||
| Assess | ||||||
| Crystal structure of HLA-B5801, a protective HLA allele for HIV-1 infection |
Heteromer P01889; P61769; | |||||
| Assess | ||||||
| HLA-E*01:03 in complex with the HIV epitope, RL9HIV |
Heteromer P13747; P61769; | 2×SO4; | ||||
| Assess | ||||||
| Crystal Structure of the cross-restricted T18A TCR and HLAB4201 bound to HIV-1 Gag TL9 peptide |
Heteromer P61769; V6E0U6; | |||||
| Assess | ||||||
| Crystal structure of pHLA-B35 in complex with TU55 T cell receptor |
Heteromer P01889; P61769; | 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of C3 TCR complex with QW9-bound HLA-B*5301 |
Heteromer P61769; S6BVK3; | |||||
| Assess | ||||||
| TCR589 in complex with HIV(Pol448-456)/HLA-B35 |
Heteromer K7N5M4; P01889; P61769; Q6IRV4; | 1×NAG; 3×ZN; 1×NAG; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 7mer peptide |
Heteromer O78189; P61769; | 1×ARG; 1×GOL; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 8mer peptide |
Heteromer O78189; P61769; | 3×GOL; | ||||
| Assess | ||||||
| HLA-B*27:05 presenting an HIV-1 6mer peptide |
Heteromer O78189; P61769; | 1×ARG; | ||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,8) | homo-18-mer | |||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-12,11) | homo-6-mer | |||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-13,12) | homo-6-mer | |||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,8) | homo-6-mer | |||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein A92E in helical assembly (-13,11) | homo-6-mer | |||||
| Assess | ||||||
| Structure of the native full-length HIV-1 capsid protein in helical assembly (-13,12) | homo-6-mer | |||||
| Assess | ||||||
| HIV-1 reverse transcriptase in complex with DNA and EFdA-triphosphate, a translocation-defective RT… | homo-2-mer | 3×MG; 1×6FN; | ||||
| Assess | ||||||
| Crystal Structure of UK-453061 bound to HIV-1 Reverse Transcriptase (wild-type). | homo-2-mer | 1×ZZE; | ||||
| Assess | ||||||
| Crystal Structure of UK-453061 bound to HIV-1 Reverse Transcriptase (K103N). | homo-2-mer | 1×ZZE; | ||||
| Assess | ||||||
| HIV reverse transcriptase in complex with inhibitor 7e (NNRTI) | homo-2-mer | 1×MRX; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Reverse Transcriptase (K103N mutant) in Complex with Inhibitor M05 | homo-2-mer | 1×5MA; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase (wild type) in complex with inhibitor M05 | homo-2-mer | 1×5MA; | ||||
| Assess | ||||||
| Crystal Structure of HIV Reverse Transcriptase in complex with inhibitor 22 | homo-2-mer | 1×M22; | ||||
| Assess | ||||||
| Crystal Structure of HIV Reverse Transcriptase in complex with inhibitor 14 | homo-2-mer | 1×M14; | ||||
| Assess | ||||||
| HIV-RT with non-nucleoside inhibitor annulated pyrazole 2 | homo-2-mer | 1×PZ2; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF A MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMQ+M184V: M41L/D67N/K70R/M184V/T215Y) … | homo-2-mer | 1×NVP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF M41L/T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMN) IN COMPLEX WITH NEVIRAPINE | homo-2-mer | 1×PO4; 1×NVP; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase in complex with N1-heterocycle pyrimidinedione non… | homo-2-mer | 1×KR1; 4×SO4; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase in complex with N1-ethyl pyrimidinedione non-nucle… | homo-2-mer | 1×KRV; 5×SO4; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase in complex with N1-butyl pyrimidinedione non-nucle… | homo-2-mer | 1×KBT; 6×SO4; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase in complex with N1-propyl pyrimidinedione non-nucl… | homo-2-mer | 1×KRP; 5×SO4; | ||||
| Assess | ||||||
| Crystal structure of V108I mutant HIV-1 reverse transcriptase in complex with nevirapine | homo-2-mer | 1×NVP; | ||||
| Assess | ||||||
| HIV-1 Reverse Transcriptase in complex with a phosphonate analog of nevirapine | homo-2-mer | 1×NVE; 4×SO4; 1×MG; 2×CL; | ||||
| Assess | ||||||
| HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES | homo-2-mer | 1×U05; | ||||
| Assess | ||||||
| MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY NON-NUCLEOSIDE INHIBITORS | homo-2-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH TNK-651 | homo-2-mer | 1×TNK; | ||||
| Assess | ||||||
| HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES | homo-2-mer | 1×HEF; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC10 | homo-2-mer | 1×PO4; 1×UC2; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC781 | homo-2-mer | 1×PO4; 1×UC1; | ||||
| Assess | ||||||
| Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with UC-781 | homo-2-mer | 2×PO4; 1×UC1; | ||||
| Assess | ||||||
| HIV Reverse Transcriptase with compound Pyr02 | homo-2-mer | 1×9PJ; | ||||
| Assess | ||||||
| HIV Reverse Transcriptase with compound Pyr01 | homo-2-mer | 1×9QI; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH MKC-442 | homo-2-mer | 1×MKC; | ||||
| Assess | ||||||
| Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with TNK-651 | homo-2-mer | 1×TNK; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC38 | homo-2-mer | 1×PO4; 1×UC3; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 1051U91 | homo-2-mer | 2×PO4; 1×U05; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE | homo-2-mer | 1×MG; 1×TB9; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH BHAP U-90152 | homo-2-mer | 1×SPP; | ||||
| Assess | ||||||
| HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES | homo-2-mer | 1×AAP; | ||||
| Assess | ||||||
| HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR RT-INHIBITOR COMPLEXES | homo-2-mer | 1×MG; 1×NVP; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 reverse transcriptase in complex with S-1153 | homo-2-mer | 1×S11; | ||||
| Assess | ||||||
| Crystal structure of V106A mutant HIV-1 reverse transcriptase in complex with UC-781 | homo-2-mer | 1×UC1; | ||||
| Assess | ||||||
| AZT DRUG RESISTANT HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH 1051U91 | homo-2-mer | 1×U05; | ||||
| Assess | ||||||
| HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH UC84 | homo-2-mer | 1×PO4; 1×UC4; | ||||
| Assess | ||||||
| Crystal structure of L100I mutant HIV-1 reverse transcriptase in complex with nevirapine | homo-2-mer | 1×NVP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF M184V MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE | homo-2-mer | 2×PO4; 1×NVP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH NEVIRAPINE | homo-2-mer | 2×PO4; 1×NVP; | ||||
| Assess | ||||||
| Crystal Structure of E138K Mutant HIV-1 Reverse Transcriptase in Complex with PETT-2 | homo-2-mer | 2×PO4; 1×PC0; | ||||
| Assess | ||||||
| HIV-1 INTEGRASE CATALYTIC CORE AND C-TERMINAL DOMAIN | homo-2-mer | 4×CPS; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE HIV-1 INTEGRASE CATALYTIC CORE DOMAIN | homo-2-mer | 4×CD; 2×CL; 4×SO4; | ||||
| Assess | ||||||
| HIV Integrase Catalytic Domain containing F185K + A124T mutations complexed with GSK0002 | homo-2-mer | 4×CAC; 8×SO4; 6×EDO; 2×65P; | ||||
| Assess | ||||||
| HIV Integrase Catalytic Domain containing F185K + A124N + T125A mutations complexed with GSK0002 | homo-2-mer | 4×CAC; 4×SO4; 2×EDO; 2×65P; | ||||
| Assess | ||||||
| HIV Integrase Catalytic Domain containing F185K + A124N + T125S mutations complexed with GSK0002 | homo-2-mer | 4×CAC; 6×SO4; 2×EDO; 2×65P; | ||||
| Assess | ||||||
| Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase | homo-2-mer | 4×CD; 2×CL; 4×SO4; 1×MG; 2×AVX; 1×DTV; 1×DTT; | ||||
| Assess | ||||||
| HIV Integrase Catalytic Domain containing F185K mutation complexed with GSK0002 | homo-2-mer | 4×CAC; 2×SO4; 4×EDO; 2×65P; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Integrase Catalytic Core Domain with Inhibitor Peptide | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 wild type protease with GRL-04315A, a tetrahydronaphthalene carboxamide with (R)-Boc-amine an… | homo-2-mer | 1×NA; 2×CL; 1×GA5; 1×ACT; 1×GOL; | ||||
| Assess | ||||||
| HIV-1 wild type protease with GRL-02815A, a thiochroman heterocycle with (S)-Boc-amine functionalit… | homo-2-mer | 1×NA; 2×CL; 1×GOL; 1×GA8; | ||||
| Assess | ||||||
| Wild-type HIV-1 protease in complex with tipranavir | homo-2-mer | 1×NA; 3×CL; 3×GOL; 1×TPV; | ||||
| Assess | ||||||
| HIV-1 WILD TYPE PROTEASE WITH GRL-034-17A, (3aS, 5R, 6aR)-2-OXOHEXAHYD CYCLOPENTA[D]-5-OXAZOLYL URE… | homo-2-mer | 2×NA; 2×CL; 1×J0S; 1×FMT; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Protease Inhibitors Containing Substituted fused-Tetrahydropyranyl Tetra… | homo-2-mer | 1×5B7; 2×NA; 3×CL; 1×ACT; | ||||
| Assess | ||||||
| Wild-type HIV-1 protease in complex with Lopinavir | homo-2-mer | 1×NA; 3×CL; 1×AB1; | ||||
| Assess | ||||||
| HIV-1 wild type protease with GRL-110-19A, a chloroacetamide derivative based on Darunavir as P2' g… | homo-2-mer | 1×NA; 3×CL; 1×GOL; 1×X7H; | ||||
| Assess | ||||||
| HIV-1 wild type protease with GRL-042-17A, 3-phenylhexahydro-2h-cyclopenta[d]oxazol-2-one with a bi… | homo-2-mer | 1×HWY; 2×NA; 4×CL; | ||||
| Assess | ||||||
| HIV-1 protease with mutation L76V in complex with GRL-5010 (gem-difluoro-bis-tetrahydrofuran as P2 … | homo-2-mer | 1×NA; 3×CL; 2×GOL; 1×G10; 2×ACT; | ||||
| Assess | ||||||
| HIV protease in complex with benzoxaborolone analog of darunavir | homo-2-mer | 1×GOL; 3×CL; 1×NA; 1×ACT; 1×X7B; | ||||
| Assess | ||||||
| D30N mutant HIV protease in complex with benzoxaborolone analog of darunavir | homo-2-mer | 1×GOL; 3×CL; 1×X7B; | ||||
| Assess | ||||||
| HIV-1 protease with single mutation L76V in complex with Lopinavir | homo-2-mer | 1×NA; 3×CL; 1×AB1; | ||||
| Assess | ||||||
| Structure of wild-type HIV protease in complex with degraded photosensitive inhibitor | homo-2-mer | 2×BME; 1×3EN; | ||||
| Assess | ||||||
| HIV-1 protease with single mutation L76V in complex with tipranavir | homo-2-mer | 1×NA; 2×CL; 3×GOL; 1×ACT; 1×TPV; | ||||
| Assess | ||||||
| Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of … | homo-2-mer | 3×PO4; 3×ACT; 1×017; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 Protease Inhibitor GRL-105-11A Containing Substituted fused-Tetrahydropy… | homo-2-mer | 1×5B5; 1×NA; 3×CL; | ||||
| Assess | ||||||
| Crystal structure of HIV1 protease in situ product complex | homo-2-mer | |||||
| Assess | ||||||
| Structure of wild-type HIV protease in complex with photosensitive inhibitor PDI-6 | homo-2-mer | 1×3EM; | ||||
| Assess | ||||||
| HIV-1 protease with mutation L76V in complex with GRL-0519 (tris-tetrahydrofuran as P2 ligand) | homo-2-mer | 2×NA; 5×CL; 4×GOL; 1×G52; | ||||
| Assess | ||||||
| HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS | homo-2-mer | 1×146; | ||||
| Assess | ||||||
| MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS | homo-2-mer | 1×216; | ||||
| Assess | ||||||
| RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS | homo-2-mer | 1×XK2; | ||||
| Assess | ||||||
| HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY | homo-2-mer | 1×DMP; | ||||
| Assess | ||||||
| NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV PROTEASE INHIBITORS | homo-2-mer | 1×Q82; | ||||
| Assess | ||||||
| Crystal structure of wild type HIV-1 protease in complex with GRL-10413 | homo-2-mer | 1×G43; | ||||
| Assess | ||||||
| HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY | homo-2-mer | 1×XV6; | ||||
| Assess | ||||||
| HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY | homo-2-mer | 1×846; | ||||
| Assess | ||||||
| Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of … | homo-2-mer | 4×PO4; 1×017; 1×ACT; | ||||
| Assess | ||||||
| HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS | homo-2-mer | 1×XV6; | ||||
| Assess | ||||||
| Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of … | homo-2-mer | 1×017; 1×GOL; 1×PO4; | ||||
| Assess | ||||||
| STRUCTURE OF HIV-1 PROTEASE COMPLEX | homo-2-mer | 1×DMQ; | ||||
| Assess | ||||||
| COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WIT… | homo-2-mer | 1×XV6; | ||||
| Assess | ||||||
| HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130 | homo-2-mer | 1×LP1; | ||||
| Assess | ||||||
| HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 Proteinase mutant A71T, V82A | homo-2-mer | 1×0E8; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPA… | homo-2-mer | 1×1ZK; | ||||
| Assess | ||||||
| HIV-1 PROTEASE (I84V) COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS | homo-2-mer | 1×XV6; | ||||
| Assess | ||||||
| Native HIV-1 Proteinase | homo-2-mer | 1×0E8; | ||||
| Assess | ||||||
| HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY | homo-2-mer | 1×146; | ||||
| Assess | ||||||
| HIV-1 proteinase complexed with RO 31-8959 | homo-2-mer | 1×ROC; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF AN IN VIVO HIV-1 PROTEASE MUTANT IN COMPLEX WITH SAQUINAVIR: INSIGHTS INTO THE… | homo-2-mer | 2×ROC; | ||||
| Assess | ||||||
| Wild type HIV protease bound with GW0385 | homo-2-mer | 4×K; 1×385; | ||||
| Assess | ||||||
| X-RAY ANALYSIS OF HIV-1 PROTEINASE AT 2.7 ANGSTROMS RESOLUTION CONFIRMS STRUCTURAL HOMOLOGY AMONG R… | homo-2-mer | |||||
| Assess | ||||||
| HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR, 28 STRUCTURES | homo-2-mer | 1×DMP; | ||||
| Assess | ||||||
| HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR MINIMIZED AVERAGE STRUCTURE | homo-2-mer | 1×DMP; | ||||
| Assess | ||||||
| A high-resolution NMR structure of the dimeric C-terminal domain of HIV-1 CA | homo-2-mer | |||||
| Assess | ||||||
| C-terminal domain of HIV-1 integrase, crystal structure | homo-2-mer | 7×GOL; | ||||
| Assess | ||||||
| Crystal structure of a HIV p51 (219-230) deletion mutant | monomer | 1×EDO; | ||||
| Assess | ||||||
| SOLUTION STRUCTURE OF THE RNASE H DOMAIN OF THE HIV-1 REVERSE TRANSCRIPTASE IN THE PRESENCE OF MAGN… | monomer | |||||
| Assess | ||||||
| Crystal Structure of HIV-1 RNase H with engineered E. coli loop and N-hydroxy quinazolinedione inhi… | monomer | 2×MN; 1×SO4; 1×QID; | ||||
| Assess | ||||||
| Crystal Structure of HIV-1 RNase H p15 with engineered E. coli loop and pyrimidinol carboxylic acid… | monomer | 2×MN; 1×SO4; 1×P1Y; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 1×ECW; 2×MN; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 2×MN; 2×ZN; 1×EGI; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 2×MN; 3×ZN; 1×E9B; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 2×MN; 1×E58; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic a… | monomer | 2×MN; 1×V9O; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic a… | monomer | 2×MN; 1×VA9; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 2×MN; 1×E81; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with nitrofura… | monomer | 2×MN; 2×ZN; 1×E6I; | ||||
| Assess | ||||||
| Crystal structure of engineered HIV-1 Reverse Transcriptase RNase H domain complexed with laccaic a… | monomer | 2×MN; 1×V96; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of N88D mutant HIV-1 Protease | monomer | |||||
| Assess | ||||||
| HIV-1 protease tethered dimer Q-product complex along with nucleophilic water molecule | monomer | 2×PPN; 2×GLU; | ||||
| Assess | ||||||
| Crystal Structure of N88S mutant HIV-1 Protease | monomer | |||||
| Assess | ||||||
| X-ray structure of HIV-1 protease in situ product complex | monomer | |||||
| Assess | ||||||
| Crystal structure of drug resistant V82S/V1082S HIV-1 Protease | monomer | |||||
| Assess | ||||||
| HUMAN IMMUNODEFICIENCY VIRUS, NMR, MINIMIZED AVERAGE STRUCTURE | monomer | |||||
| Assess | ||||||
| HIV-1 Protease D30N mutant | monomer | |||||
| Assess | ||||||
| D30N tethered HIV-1 protease dimer/saquinavir complex | monomer | 1×ROC; | ||||
| Assess | ||||||
| D30N HIV Protease in complex with Saquinavir | monomer | 1×ROC; | ||||
| Assess | ||||||
| 1.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE | monomer | |||||
| Assess | ||||||
| HIV-1 Protease D30N mutant in complex with Nelfinavir | monomer | 2×1UN; | ||||
| Assess | ||||||
| Crystal Structure Analysis of the non-active site mutant of tethered HIV-1 protease to 2.1A resolut… | monomer | |||||
| Assess | ||||||
| Crystal Structure of G48V/C95F tethered HIV-1 Protease/Saquinavir complex | monomer | 1×ROC; | ||||
| Assess | ||||||
| HIV-1 reverse transcriptase thumb subdomain | monomer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE OF NCP7 FROM HIV-1 | monomer | 2×ZN; | ||||
| Assess | ||||||
9 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6rwm.1.A | homo-12-mer | 0.75 | 8×ZN; | 74.65 | ||
| Assess | ||||||
| 6rwl.1.A | monomer | 0.73 | 1×ZN; | 74.65 | ||
| Assess | ||||||
| 6rwl.1.B | monomer | 0.73 | 1×ZN; | 74.65 | ||
| Assess | ||||||
| 6v3k.3.A | homo-4-mer | 0.72 | 93.61 | |||
| Assess | ||||||
| 7t15.1.E | homo-6-mer | 0.71 | 84.42 | |||
| Assess | ||||||
| 7sep.1.A | homo-2-mer | 0.71 | 98.76 | |||
| Assess | ||||||
| 5u1c.1.A | homo-4-mer | 0.70 | 93.23 | |||
| Assess | ||||||
| 1l6n.1.A | monomer | 0.69 | 95.76 | |||
| Assess | ||||||
| 7asl.1.A | homo-18-mer | 0.65 | 99.57 | |||
| Assess | ||||||